


# MVISION



## Dose+

### AI-Guided Plan Optimisation

# Dose+

## AI-Guided Plan Optimisation

for radiotherapy planning



**AI-powered dose prediction** to support consistent, efficient, and personalised radiotherapy treatment planning optimisation.

\*Dose+ is Class IIa CE-marked under MDR and FDA 510(k) pending, not available in all markets.

# 70%


Reduced Human Interactions (up to.)

# +90%

Clinical Acceptance Rate


# 2min

Average Processing Time



**Dose+ is an AI-powered solution designed to support plan optimisation for prostate and pelvic lymph node radiotherapy.** Using machine learning techniques to generate patient-specific dose predictions, Dose+ helps radiation oncology professionals plan more efficiently. By analysing individual anatomy, it delivers tailored 3D dose estimates that align with clinical best practices.

Dose+ creates clinically achievable VMAT dose distributions from CT images and structure sets using a simple DICOM transfer. These 3D dose distributions can be imported into any DICOM-compliant treatment planning system, offering a strong starting point for plan refinement. By improving efficiency and consistency, Dose+ helps maintain high plan quality across different planning scenarios.



# Features and Benefits

- **Personalised planning**

Moves beyond generic templates with dose predictions that adapt to individual patient anatomy and target prescriptions.

- **Enhanced planning consistency**

Reduces inter-planner variability in dose planning, helping to create more consistent and reproducible treatment plans.

- **Increased efficiency**

Streamlines treatment planning with achievable starting points, reducing manual adjustments and saving clinicians time.


- **Clinical confidence**

Clinically validated across multiple international institutions, demonstrating strong performance across different treatment planning systems.

- **Seamless Integration**


Compatible with all DICOM-compliant treatment planning systems, requiring no local tuning or customisation.

# Specialised AI Models for Prostate and Pelvic Radiotherapy



**Dose+** features two specialised AI models for prostate and pelvic lymph node radiotherapy, clinically validated across multiple institutions. The prostate model supports inverse planning for localised prostate cancer, while the pelvic LN model assists in cases involving lymph nodes. Both models generate achievable VMAT-style dose distributions, serving as personalised starting points in defining objectives before plan optimisation.

The system supports all standard fractionation schemes, including simultaneous integrated boost techniques, requiring only standard anatomical structures with associated target dose for prediction. With consistent performance across cases, the models do not require local tuning or adjustments, allowing for immediate clinical implementation and improved workflow efficiency.



## Prostate Model


Specialised AI model for prostate cancer cases without nodal involvement. Supports all fractionation approaches – from conventional to SBRT – with capability for simultaneous integrated boost techniques.

## Pelvic LN Model

Specialised AI model for prostate cancer treatments with lymph node involvement. Supports conventional and moderate hypofractionation, with capabilities for complex simultaneous integrated boost techniques.



# GDPR & HIPAA Compliant Workflow





## Training and customer service

The Dose+ solution is easy to install and configure. Training is available online and on-premises. Any issue will be solved quickly by our dedicated customer service team.

## Updates

The Dose+ solution will be updated via the cloud after a new release or changes to contouring guidelines.

## Artificial intelligence (AI)

The Dose+ solution uses an AI algorithm called deep-learning neural network. These neural networks attempt to simulate the behaviour of the human brain, allowing it to “learn” from large amounts of data.

*“The introduction of Dose+ marks an important milestone in our mission to enhance radiation therapy workflows through AI innovation. Building on the success of our Contour+ AI segmentation service, Dose+ further demonstrates our commitment to developing practical solutions that enable clinicians to spend more time focusing on patient care while maintaining the highest standards of treatment quality.”*

**Saad Ullah Akram**, CEO of MVision AI



---

**MVision AI**

Paciuksenkatu 29  
00270 Helsinki, Finland  
info@mvision.ai

[www.mvision.ai](http://www.mvision.ai)